Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.63% | -27.40% | 6.34% | -76.35% | -90.52% |
| Total Depreciation and Amortization | 14.54% | 12.07% | 11.75% | 0.00% | 13.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 169.84% | 261.10% | 1,236.71% | 167.64% | 102.17% |
| Change in Net Operating Assets | -90.17% | 189.82% | -295.90% | 154.91% | -75.31% |
| Cash from Operations | -0.59% | 124.64% | -84.38% | 453.65% | 63.08% |
| Capital Expenditure | -10.61% | -35.70% | -15.89% | -95.58% | -10.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -98.92% | -- |
| Other Investing Activities | 47.93% | -3.99% | -94.90% | 96.55% | 9.73% |
| Cash from Investing | 40.07% | -12.26% | -208.79% | 65.61% | -115.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.19% | -5.94% | 38.08% | 12.94% | 0.58% |
| Repurchase of Common Stock | 74.22% | -869.09% | -69.09% | -40,500.00% | 46.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.68% | -180.00% | 142.86% | -3,200.00% | -2,214.71% |
| Cash from Financing | 86.38% | -100.57% | -74.88% | -139.86% | 24.22% |
| Foreign Exchange rate Adjustments | -940.00% | 112.84% | 146.33% | -93.14% | 98.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.06% | 227.34% | -646.67% | 139.18% | -129.39% |